PHAR צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Pharming

Pharming Group N.V. (PHAR) develops high-cost biologics from the milk of transgenic rabbits, monetizing the treatment of rare pathologies through insurance company payouts. Quarterly earnings per share (EPS) growth demonstrates the precise execution of financial plans, with the indicator currently standing at 175.50. High regulatory barriers and patent protection for Ruconest preclude the emergence of generics, ensuring business stability.

Quarterly EPS growth distinguishes short-term impulses from the asset's fundamental nature, revealing periods where cost pressures squeeze margins. This metric measures the dynamics of net profit per share, determining the efficiency of capital management. By analyzing quarterly earnings per share growth, an investor assesses the resilience of financial results against inflation. For Pharming Group N.V. (PHAR), this indicator reflects the monetization of recombinant proteins. EPS growth confirms the commercial success of therapies for rare genetic diseases.